CVRx, Inc. (CVRX)
Market Cap | 376.57M |
Revenue (ttm) | 47.26M |
Net Income (ttm) | -58.48M |
Shares Out | 24.26M |
EPS (ttm) | -2.71 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 283,173 |
Open | 15.66 |
Previous Close | 15.52 |
Day's Range | 15.49 - 15.95 |
52-Week Range | 6.40 - 33.14 |
Beta | 1.11 |
Analysts | Buy |
Price Target | 15.83 (+2.0%) |
Earnings Date | Oct 29, 2024 |
About CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an... [Read more]
Financial Performance
In 2023, CVRx, Inc.'s revenue was $39.30 million, an increase of 74.89% compared to the previous year's $22.47 million. Losses were -$41.20 million, -0.55% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price forecast is $15.83, which is an increase of 2.00% from the latest price.
News
CVRx: Impressive Top-Line Growth Seems Priced In
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a...
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oas...
CVRx announces new CPT® Category I codes for Barostim
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial...
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...
CVRx Announces Appointment of Two New Board Members
Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (...
The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Shareholders Urged To Participate In Fraud Inquiry With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Shareholders Invited To Join Fraud Inquiry With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Investors May Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("C...
CVRx Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
CVRx Inc Investors Can Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
CVRx Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
CVRx Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CV...
CVRx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CVRX
LOS ANGELES , Aug. 5, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX) for violations of §§10(b) and 20(a)...
CVRX Investors Have Opportunity to Join CVRx, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Aug. 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or...
CVRx Announces Increased Inpatient Payment for Barostim Procedure
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has ...
CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Gen...
CVRx, Inc. (CVRX) Q2 2024 Earnings Call Transcript
CVRx, Inc. (NASDAQ:CVRX) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participan...
CVRx Reports Second Quarter 2024 Financial and Operating Results
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024
MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...